MYX
MAYNE PHARMA GROUP LIMITED
$2.54
▲ +0.79%
Market cap
$208M
Turnover
$379,552
Last price
$2.54
Day change
+0.79%
Announcements
9
Range, past year
Open 5.530 · Low 2.020 · Now 2.540 · High 7.160
Open MYX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
MYX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
28/100
Wyckoff phase
Accumulation46d
Trend stage
Breakdown
1 Day
+0.8%
1 Week
-10.2%
1 Month
-17.0%
1 Year
-54.6%
RSI
28
Avg daily range
3.9%
MAYNE PHARMA GROUP LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Accumulation, where it has been for 46 trading days. The weekly timeframe reads Accumulation, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- RSI oversold (28)
- 60d drawdown -24.8%
- Risk rating: High
- Composite downside risk elevated
MYX announcements
Recent price-sensitive releases.
- 2026-09-30 MYX settles US patent litigation re Imvexxy with Sun Pharma Progress Report | Legal Proceedings
- 2026-08-27 2026 Full Year Results Media Release Web Cast | Preliminary Final Report
- 2026-08-27 2026 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-31 Mayne Pharma reports unaudited Q4 and FY26 results Notification of Results/Reporting Date | Trading Update | Periodic Reports - Other
- 2026-06-05 Mayne Pharma receives $14.4m for legal costs from Cosette
- 2026-05-22 Court awards MYX $13.27m for legal costs from Cosette
- 2026-04-29 Mayne Pharma reports unaudited 3Q FY26 results
More Health Care stocks
Most traded in the same sector.